B Cell Lymphoma Clinical Trial
Official title:
A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies
A total of 40 participants will be recruited, with 20 participants in each of the following subcategories: A) High grade lymphoma (DLBCL, FL grade 3b, transformed FL) (n=20) B) Low grade lymphoma (e.g. FL grade 1, 2 or 3a, MZL, MCL) (n=20) The main purpose for having two experimental treatment arms is to provide a comparator for the translational endpoints, i.e. to assess whether the differences observed are due to the addition of varlilumab to rituximab. The only difference between Arm A and Arm B is the delay in administration of varlilumab in cycle 1, which is on Day 2 in Arm A and Day 8 in Arm B. As the post-treatment tissue collection occurs on Day 7/8, prior to administration of varlilumab in Arm B, samples will be obtained from participants that have either been treated with rituximab alone, or both rituximab and varlilumab. To minimise any potential risks to the patient as a result of a repeat biopsy on Day 7/8, a prerequisite for entry to the trial is that the participants must have accessible sites for biopsy. Difference in response rates between Arm A and Arm B are not expected.
A multicentre, randomised, phase IIa study in participants with relapsed or refractory CD20+ B-cell malignancies. The study will be conducted in 2 stages as follows: Stage 1 - Safety During the safety phase, 6 participants (3 from each Arm and from any subtype) will be treated as detailed in section 6.1. The number of dose limiting toxicities (DLTs) experienced by these participants in each arm after having completed the first cycle will dictate whether the trial will proceed to the second stage. 1. In each arm, if out of these 3 participants 0 experience a DLT, then that arm will proceed to stage 2. 2. In each arm, if out of these 3 participants 1 or 2 experience a DLT, then that arm will be expanded to 3 more participants. 1. If 1 or 2 out of 6 participants experience a dose limiting toxicity, the arm will proceed to Stage 2. 2. If 3 or more out of 6 participants experience a DLT, recruitment for that arm will be stopped. 3. If out of these 3 participants, 3 experience a dose limiting toxicity, recruitment for that arm will be stopped. Initially, the first patient will be entered into the trial. Providing there are no serious or unexplained safety issues during the first 2 weeks, as determined by the Safety Review Committee (SRC), then dosing of subsequent participants will continue as they are identified. Should toxicity findings of concern occur, the SRC may choose to stagger the start of dosing for subsequent participants and/or cohorts. The objective of Stage 2 is to obtain some further information on the safety of the intervention in a larger sample, information on activity (response rate overall and per lymphoma subtype) and feasibility of administrating rituximab and varlilumab together. During Stage 2, recruitment will continue so (including those in Stage 1), there is a total of 10 participants per arm and per disease category (a total of 20 participants per disease category, 40 participants in the trial in total). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Withdrawn |
NCT02547948 -
CD19-targeting CAR T Cells for B Cell Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03258047 -
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03478514 -
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
Recruiting |
NCT06415708 -
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT03670888 -
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
|
Phase 1 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Recruiting |
NCT06213311 -
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT04008251 -
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04637763 -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
|
Phase 1 | |
Recruiting |
NCT04782193 -
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03146533 -
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
|
Phase 1/Phase 2 | |
Recruiting |
NCT05385263 -
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
|
Phase 2 | |
Recruiting |
NCT03366324 -
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT03929107 -
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
|
Phase 2 | |
Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
Recruiting |
NCT04289220 -
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT03383952 -
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
|
Phase 1 |